Long Term Safety of SL77.0499-10 (Alfuzosin) in Patients With BPH

Inclusion Criteria: * Having a symptomatic BPH diagnosed clinically by digital rectal examination and ultrasonography * Suffering for at least 6 months from lower urinary tract symptoms related to BPH * An I-PSS total score ≥ 13 * Out patient Exclusion Criteria: * Patients previously treated with SL77.0499-10. * Neurogenic bladder dysfunction, confirmed or suspected, irrespective of aetiology. * Isolated bladder neck disease. * Diagnosed carcinoma of the prostate. * Previous prostatic surgery or other invasive procedures (thermotherapy…) for the treatment of BPH. * Patients having an indwelling catheter. * A residual urine \> 200mL. * Patients with Moderate or sever hepatic insufficiency. * Known hypersensitivity to alpha1-blockers. * Patients who have received anti-androgens, 5alpha-reductase inhibitors, LH-RH analogues within the previous 3 months before Screening * Patients judged inappropriate for admission to the study by the Investigator or the Sub-Investigator.